SAN FRANCISCO--(BUSINESS WIRE)--Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of Clinvest Research, an established site based in Springfield, Missouri. Founded in 1996, Clinvest Research has conducted over 600 trials for chronic diseases and conditions such as headache and migraine, arthritis and chronic pain, and diabetes, as well as weight loss.
“The acquisition of Clinvest Research strengthens our chronic pain and endocrinology expertise and increases participant access to clinical trials for highly prevalent diseases and conditions that often remain undiagnosed and untreated,” said Cathy Collins, CEO of Headlands Research. “Our rapid expansion represents our ongoing commitment to raising awareness of these conditions, supporting medical innovation, and improving lives.”
By combining Clinvest Research’s expertise with the 11 other sites in the Headlands Research site network studying chronic conditions, Headlands Research is able to access a greater participant population for clinical trials conducted in the United States and Canada, furthering the understanding of disease and filling treatment gaps. Originally a small primary care and headache specialty clinic, the clinical trials conducted at Clinvest Research have had a significant impact on the medical community’s understanding and treatment of migraines. Affecting 39 million people in the United States, migraines can be debilitating, and a considerable proportion of affected individuals do not receive the diagnosis and treatment they need.
With the rapidly aging population, rates of age-related chronic conditions such as arthritis are increasing, with more than 58 million U.S. adults diagnosed with arthritis and an estimated 78.4 million expected to be diagnosed by 2040. In addition, approximately 37 million children and adults in the United States have diabetes, with the highest rates observed in American Indians and Alaska Natives, Black people, people of Hispanic origin, people with lower education levels, and families living below the poverty level.
“Invisible chronic conditions can severely limit people’s function and quality of life. So, to our patients, medical research means hope,” said Ryan Cady, owner and CEO of Clinvest Research. “Headlands Research’s participant-centric approach is a perfect fit for us, and we’re excited to combine resources to further research so we can bring new treatments to the people who can benefit from them.”
By focusing on experienced principal investigators and clinicians and access to a diverse participant population, the Headlands Research network of clinical research sites aims to improve lives by advancing innovative medical therapies. Headlands Research also recently announced the launch of Headlands Research Detroit as well as the acquisition of Headlands Eastern Massachusetts and has plans to continue expanding its network throughout 2023.
To learn more about Headlands Research and its extensive network of research sites, visit https://headlandsresearch.com, contact info@headlandsresearch.com, or follow the company on LinkedIn.
About Headlands Research
Headlands Research is a multinational integrated clinical trial site organization with a mission to improve lives by advancing innovative medical therapies. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com.
